Translational Molecular Imaging
Dr David Lewis
Head of Translational Molecular Imaging Facility
The Translational Molecular Imaging (TMI) centre, headed by Dr David Lewis, advances novel imaging technologies and acts as a shared resource for Beatson Institute and Glasgow Cancer Centre researchers serving as a hub for emerging imaging research and technology.
The TMI operates over two sites: the CRUK Beatson Institute at the Garscube campus and the West of Scotland PET Centre at Beatson West of scotland Cancer Centre. The state-of-the-art facilities and equipment include access to a GE cyclotron, dedicated research radiosynthesizers, a small-animal PET/MRI facility and two clinical GE Discovery Time-of-Flight PET/CT scanners. Within the TMI there is expertise in several key areas of imaging, which is further supported by a wide network of expert collaborators. The TMI drives collaborative imaging research across this network making the best available imaging technologies and expertise available to all preclinical and clinical researchers. The focus is on developing and applying innovative imaging technologies such as new PET radiotracers and MRI methodology, which can aid in the visualisation, measurement and understanding of cancer biology. The goal is to answer basic scientific questions and clinically translate novel imaging technology for improving the molecular diagnosis of cancer, a current area of unmet need.
Projects in the TMI range from standard imaging studies where access to technology is facilitated and users are guided in applications such as preclinical tumour screening and assessment of treatment response to much wider scale projects where the TMI acts as a collaborative partner in the production and validation of novel imaging agents, the development of novel pharmacodynamic biomarkers and in vivo molecular phenotyping. The unique opportunity at the Beatson is to guide collaborative research using the world-class cancer models at the Institute and to use those models to develop clinical imaging biomarkers for novel applications such as improved tumour classification, patient stratification and personalised cancer therapy.
David Lewis also leads the Molecular Imaging research group.
Beatson Cancer Charity, Beatson Endowment
Witney TH, Lewis DY. Imaging Cancer Metabolism with Positron Emission Tomography (PET). 2019; Cancer Metabolism - Springer
Gonzalez PS, O'Prey J, Cardaci S, Barthet VJA, Sakamaki JI, Beaumatin F, Roseweir A, Gay DM, Mackay G, Malviya G, Kania E, Ritchie S, Baudot AD, Zunino B, Mrowinska A, et al. Mannose impairs tumour growth and enhances chemotherapy. Nature 2018; 563: 719-23
Zmuda F, Blair A, Liuzzi M, Malviya G, Chalmers AJ, Lewis D, Sutherland A, Pimlott SL. An 18F-labeled poly(ADP-ribose) polymerase positron emission tomography imaging agent. J Med Chem 2018; 61: 4103-14.
Morran DC, Wu J, Jamieson NB, Mrowinska A, Kalna G, Karim SA, Au AY, Scarlett CJ, Chang DK, Pajak MZ; Australian Pancreatic Cancer Genome Initiative (APGI), Oien KA, McKay CJ, Carter CR, Gillen G, Champion S, Pimlott SL, Anderson KI, Evans TR, Grimmond SM, Biankin AV, Sansom OJ, Morton JP. Targeting mTOR dependency in pancreatic cancer. Gut. 2014;63(9):1481-9.
Rosenfeldt MT, O'Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, Au A, Rai TS, Zheng L, Ridgway R, Adams PD, Anderson KI, Gottlieb E, Sansom OJ, Ryan KM. p53 status determines the role of autophagy in pancreatic tumour development. Nature. 2013;504(7479):296-300.
Najumudeen AK, Ceteci F, Fey SK, Hamm G, Steven RT, Hall H, Nikula CJ, Dexter A, Murta T, Race AM, Sumpton D, Vlahov N, Gay DM, Knight JRP, Jackstadt R, Leach JDG, Ridgway RA, Johnson ER, Nixon C, Hedley A, et al. The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. Nat Genet. 2021;53:16-26.
Cicone F, Malviya G, Sambuceti G. Editorial: Perspectives in Small Animal Radionuclide Imaging. Frontiers in Medicine. 2020;7.
Malviya G, Patel R, Salji M, Martinez RS, Repiscak P, Mui E, Champion S, Mrowinska A, Johnson E, AlRasheedi M, Pimlott S, Lewis D, Leung HY. 18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy. EJNMMI Research. 2020;10(1):143.
Patel R, Brzezinska EA, Repiscak P, Ahmad I, Mui E, Gao M, Blomme A, Harle V, Tan EH, Malviya G, Mrowinska A, Loveridge CJ, Rushworth LK, Edwards J, Ntala C, Nixon C, Hedley A, Mackay G, Tardito S, Sansom OJ, Leung HY. Activation of beta-catenin cooperates with loss of Pten to drive AR-independent castration-resistant prostate cancer. Cancer research.
Serrao EM, Kettunen MI, Rodrigues TB, Lewis DY, Gallagher FA, Hu DE, Brindle KM. Analysis of (13) C and (14) C labeling in pyruvate and lactate in tumor and blood of lymphoma-bearing mice injected with (13) C- and (14) C-labeled pyruvate. NMR Biomed 2018;31(5):e3901.
Zmuda F, Blair A, Liuzzi MC, Malviya G, Chalmers AJ, Lewis D, Sutherland A, Pimlott SL. An (18)F-Labeled Poly(ADP-ribose) Polymerase Positron Emission Tomography Imaging Agent. J Med Chem 2018;61(9):4103-14.
Neves AA, Xie B, Fawcett S, Alam IS, Witney TH, de Backer MM, Summers J, Hughes W, McGuire S, Soloviev D, Miller J, Howat WJ, Hu DE, Rodrigues TB, Lewis DY, Brindle KM. Rapid Imaging of Tumor Cell Death in vivo using the C2A domain of Synaptotagmin-I. J Nucl Med 2017; 58: 881–7
Brindle KM, Izquierdo-Garcia JL, Lewis DY, Mair RJ, Wright AJ. Brain Tumor Imaging. J Clin Oncol 2017; 35: 2432–38
Vis R, Malviya G, Signore A, Grutters JC, Meek B, van de Garde EMW, Keijsers RGM. 99mTc labelled anti-TNF-α antibody for the imaging of disease activity in patients with pulmonary sarcoidosis. Eur Respir J 2016; 47(4):1198-207
Malviya G, Nayak T, Gerdes C, Dierckx RA, Signore A, de Vries EF. Isolation and 111In-Oxine Labeling of Murine NK Cells for Assessment of Cell Trafficking in Orthotopic Lung Tumor Model. Mol Pharm 2016; 13(4):1329-38